Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
暂无分享,去创建一个
M. Kris | G. Demetri | R. Herbst | B. Levin | D. Bajorin | R. Ozols | R. Winn | E. Vokes | P. Ganz | R. Mayer | R. Sawaya | G. Reaman | L. Schuchter | D. Raghavan | M. Markman | J. Sweetenham | D. Hao | L. Vahdat | D. Blum | H. Bleiberg | B. Johnson
[1] J. Meyerhardt,et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 , 2005 .
[2] M. Hudson,et al. Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study , 2005 .
[3] Mark Levine,et al. Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Rosell,et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association , 2005 .
[5] M. Pfreundschuh,et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study , 2005 .
[6] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Motzer,et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) , 2005 .
[8] J. Meyerhardt,et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. , 2005, JAMA.
[9] K. Ang,et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx , 2005 .
[10] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[11] Vikas Khurana,et al. Statins and prostate cancer risk: A large case control study in veterans , 2005 .
[12] R. Bukowski,et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[13] Richard L Wahl,et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.
[14] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[15] R. Gray,et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .
[16] R. Schilsky,et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Hainsworth,et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial , 2005 .
[18] J. Forbes,et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer , 2005 .
[19] A. Zelenetz,et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Ratain,et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[21] Patricia A. Ganz,et al. From cancer patient to cancer survivor : lost in transition , 2006 .
[22] D. Ransohoff,et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.
[23] J. Sudbø,et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer in current and former smokers - [REMOVED] , 2005 .
[24] A. Saykin,et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Robert Livingston,et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.
[26] T. Fears,et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[29] J. Roy,et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. , 2005, Journal of the National Cancer Institute.
[30] Vikas Khurana,et al. Statins to reduce breast cancer risk: A case control study in U.S. female veterans , 2005 .
[31] L. Willett. Vitamin E did not prevent cardiovascular disease and cancer in healthy women , 2006, Evidence-based medicine.
[32] S. Yusuf,et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. , 2005, JAMA.
[33] J. Manson,et al. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.
[34] Graham A. Colditz,et al. Physical activity and survival after breast cancer diagnosis , 2005 .
[35] Ronit Almog,et al. Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.
[36] Vikas Khurana,et al. Statins reduce the incidence of lung cancer: A study of half a million U.S. veterans , 2005 .
[37] C. D'Orsi,et al. Diagnostic Performance of Digital Versus Film Mammography for Breast-Cancer Screening , 2005, The New England journal of medicine.
[38] T. Pietsch,et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.
[39] B. Barlogie,et al. Results of total therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM) , 2005 .
[40] J. Meyerhardt,et al. The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 , 2005 .
[41] R. Motzer,et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .
[42] G. Demetri,et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST , 2005 .
[43] N. Coburn,et al. Significant regional variation in treatment and survival of gastric cancer , 2005 .
[44] N. Wolmark,et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 , 2005 .
[45] S. Lippman,et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] C. Vachon,et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. , 2005, JAMA.
[47] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[48] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[49] C. Gluud,et al. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis , 2004, The Lancet.
[50] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[51] J. Gardiner,et al. Cancer, Medicaid enrollment, and survival disparities , 2005, Cancer.
[52] D. Cunningham,et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) , 2005 .
[53] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[54] A. Giuliano,et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) , 2005 .
[55] E. Paulson,et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison , 2005, The Lancet.
[56] E. Guadagnoli,et al. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector? , 2005, Journal of the National Cancer Institute.
[57] Stephen D. Persell,et al. Low-Dose Aspirin Does Not Reduce Cancer Incidence in Women Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. , 2005 .
[58] P. Greenberg,et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study , 2005 .